Cardiac resynchronization therapy: results, challenges and perspectives for the future
Marcus Ståhlberg1,2, Frieder Braunschweig1,2, Fredrik Gadler1,2
1a Department of Medicine, Karolinska Institutet , Solna , Stockholm , Sweden.
Scandinavian Cardiovascular Journal : SCJ
|September 1, 2016
Summary
Cardiac resynchronization therapy (CRT) improves outcomes for heart failure patients with dyssynchronous heartbeats. CRT restores synchronized heart contractions, reducing mortality and halting disease progression.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Heart failure (HF) affects 2% of the Western population, with 15-30% of patients with reduced ejection fraction (HFrEF) exhibiting prolonged QRS duration due to left-bundle branch block (LBBB).
- Increased QRS duration signifies left ventricular (LV) dyssynchronous activation and contraction, worsening systolic function and prognosis in failing hearts.
Purpose of the Study:
- To review the mechanisms of dyssynchrony and resynchronization in HF.
- To discuss the efficacy of cardiac resynchronization therapy (CRT) based on clinical trials.
- To explore current challenges and future perspectives in CRT.
Main Methods:
- Review of randomized controlled clinical trials on CRT.
- Analysis of mechanisms underlying ventricular dyssynchrony and resynchronization.
- Discussion of patient selection and therapy optimization.
Main Results:
- CRT, using biventricular pacemakers, restores synchronous LV activation and contraction.
- Clinical trials demonstrate that CRT halts or reverses disease progression.
- CRT significantly improves clinical outcomes, including reduced mortality.
Conclusions:
- CRT is an effective therapy for selected HF patients with dyssynchronous heartbeats.
- Optimizing patient selection and therapy delivery remains crucial for CRT success.
- Future research directions include CRT for preventing adverse events, leadless pacing, and new clinical applications.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
716
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
716
01:29Cardiomyopathy V: Interprofessional Care
582
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
582
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
618
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
618
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
726
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
726
01:27Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
01:22Heart Failure VI: Adjunct Therapies
501
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
501